

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Eggert Stockfleth	Confirmation No.:	7550
Serial No.:	10/574,422	Art Unit:	1655
Filed:	November 7, 2006	Examiner:	Qiuwen Mi
Customer No.:	21559		
Title:	USE OF A POLYPHENOL FOR THE TREATMENT OF A CANCEROUS OR PRECANCEROUS LESION OF THE SKIN		

TERMINAL DISCLAIMER UNDER 37 C.F.R. §§ 1.321 and 3.73(b)

Pursuant to 37 C.F.R. § 1.321(b), MediGene AG, the assignee of the entire right, title, and interest in the above-captioned application, seeks to disclaim the terminal portion of the term of the patent to be granted on the application. This terminal disclaimer is binding on the grantee and its successors or assigns.

Pursuant to 37 C.F.R. § 1.321(b)(1), this terminal disclaimer is signed by an attorney of record.

Pursuant to 37 C.F.R. § 1.321(b)(2), MediGene AG hereby waives and disclaims the terminal portion of the term of the entire patent to be granted upon the application subsequent to the expiration date of any patent granted on U.S. Patent Application No. 10/682,612. MediGene AG does not disclaim any terminal part of any patent granted on the application prior to the expiration date of the full statutory term of a patent granted on U.S. Patent Application No. 10/682,612 in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321, has all claims canceled by a reexamination certificate, is reissued, or is otherwise terminated prior to expiration of its statutory term, except for the termination of

common ownership.

Pursuant to 37 C.F.R. § 1.321(b)(3) and § 3.73(b), the undersigned attorney/agent of record certifies that MediGene AG, a corporation, is the assignee of the entire right, title, and interest in the application by virtue of:

An assignment from the inventor of the application. The assignment was recorded in the Patent and Trademark Office at Reel 017775, Frame 0306 on April 4, 2006.


Pursuant to 37 C.F.R. § 1.321(b)(4), submitted herewith is \$140.00 for the fee set forth in 37 C.F.R. § 1.20(d).

Further, pursuant to 37 C.F.R. § 1.321(c)(3), this terminal disclaimer is being filed to overcome a provisional double patenting rejection in the application. Any patent granted on the application or any resulting patent subject to reexamination proceedings shall be enforceable only for and during such period that the patent is commonly owned with the application or patent that formed the basis for the rejection.

If there are any additional charges or any credits, please apply them to Deposit Account Number 03-2095.

Respectfully submitted,

Date: 07 December 2010



Karen L. Elbing, Ph.D.
Reg. No. 35,238

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045